The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2013 ACR/ARHP Annual Meeting: Diagnostic,Treatment Approaches Evolve for Kawasaki Disease

2013 ACR/ARHP Annual Meeting: Diagnostic,Treatment Approaches Evolve for Kawasaki Disease

February 1, 2014 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • 2013 ACR/ARHP Annual Meeting: Better Care for Pediatric Rheumatology Patients On Horizon
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
  • 2013 ACR/ARHP Annual Meeting: Inflammatory Eye Disease Management Can Benefit from Collaboration between Rheumatologists and Ophthalmologists
Explore This Issue
February 2014
Also By This Author
  • Tuhina Neogi, MD, PhD, Returns to Lead the Committee on Quality of Care
Table 2: Atypical Findings in KD
click for large version
Table 2: Atypical Findings in KD2

The modified criteria can be used to diagnose most patients, including a large percentage of the 20% to 60% of children who develop aneurysms but never meet KD criteria. Further work is needed to develop criteria to identify patients at risk for these aneurysms and tailor therapy accordingly. He emphasized that many cases of KD include unusual features such as shock physiology or acute abdominal symptoms. Among the most helpful information for clinicians trying to diagnose KD is to recognize certain findings that are seldom seen in KD (see Table 2).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Overall, he urged clinicians to keep KD in mind when seeing any febrile child and to approach diagnosis by ruling out KD. He emphasized the need for early, aggressive treatment before coronary aneurysms occur and the need for agents that can safely protect coronary arteries.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Table 3: Clinical Trials for KD Treatments
click for large version
Table 3: Clinical Trials for KD Treatments

Treatment Options

Dr. Burns reviewed clinical trial data on new treatments for KD (see Table 3).

Based on the data, she said that infliximab should be considered in children with high inflammation and those with early coronary artery changes. “A single dose of infliximab (5 mg/kg) is safe and well tolerated in patients with acute Kawasaki disease and reduces fever, inflammation, and coronary artery internal diameter faster,” she said.

Although data on atorvastatin is still pending, Dr. Burns emphasized that statins may hold promise for mitigating coronary artery damage in the acute phase.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

She also presented data from the San Diego Adult KD Collaborative study that is beginning to address the future of KD patients and cardiovascular health by looking at the effect of KD on future cardiovascular health, the risk (if any) for people with normal echocardiograms during acute illness, and the feasibility of stratifying patients based on risk using simple, noninvasive tests. Results of one study published in 2012 that looked at computed tomography (CT) calcium scores in KD patients years after KD diagnosis found no calcification in patients with a history of KD and normal coronary arteries during the acute phase of the disease, and found that coronary calcification, which may be severe, occurs late in patients with coronary aneurysms.3 These results suggest, according to Dr. Burns, the usefulness of CT calcium scoring to screen patients with a remote history of KD or suspected KD and unknown coronary artery status.

Pages: 1 2 3 | Single Page

Filed Under: Career Development, Education & Training, Meeting Reports, Professional Topics Tagged With: ACR/ARHP Annual Meeting, Cardiac, Diagnosis, drug, imaging, infliximab, Kawasaki disease, patient care, Pediatrics, Research, rheumatologist, TreatmentIssue: February 2014

You Might Also Like:
  • 2013 ACR/ARHP Annual Meeting: Better Care for Pediatric Rheumatology Patients On Horizon
  • 2015 ACR/ARHP Annual Meeting: Behçet’s Disease Poses Diagnosis, Treatment Challenges
  • 2013 ACR/ARHP Annual Meeting: Inflammatory Eye Disease Management Can Benefit from Collaboration between Rheumatologists and Ophthalmologists
  • 2013 ACR/ARHP Annual Meeting: Research Provides Insight into Preclinical Rheumatic Disease

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)